Camber Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Camber Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50,000	Closed	-$2.76M	–	39
2020 Q3	$2.76M	Buy	+50,000	New	+$3.18M	0.15%	33
2020 Q1	–	Sell	-730,000	Closed	-$58M	–	35
2019 Q4	$58M	Buy	+730,000	New	+$43.3M	2.95%	18
2019 Q2	–	Sell	-1,800,000	Closed	-$95.3M	–	36
2019 Q1	$95.3M	Sell	1,800,000 -450,000	-20%	-$22.1M	4.75%	5
2018 Q4	$92.4M	Buy	2,250,000 +175,000	+8%	+$6.56M	4.38%	8
2018 Q3	$78.8M	Sell	2,075,000 -125,000	-6%	-$5.54M	3.37%	10
2018 Q2	$99.4M	Buy	2,200,000 +1,000,000	+83%	+$45.5M	3.83%	10
2018 Q1	$58M	Buy	1,200,000 +400,000	+50%	+$22.3M	2.85%	16
2017 Q4	$31.5M	Buy	+800,000	New	+$29.9M	1.54%	22

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Camber Capital Management's GBT Position: Q4 2020 in Review

Camber Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 50,000 shares — an estimated $2.76M sold.

Camber Capital Management first reported a position in GBT in Q4 2017 and held it in 8 quarters. The position peaked at $99.4M in Q2 2018. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

Camber Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Camber Capital Management sold 50,000 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $2.76M.
Camber Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 8 quarters.
Camber Capital Management's Global Blood Therapeutics, Inc. position peaked at $99.4M in Q2 2018.
228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Camber Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.